The UNC Lineberger Comprehensive Cancer Center has been awarded $28 million by the Advanced Research Projects Agency for Health (ARPA-H). The money will be used to develop a new clinical trial for breast cancer which has spread to other part of the body. The trial, “Translational Breast Cancer Research Consortium Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies,” which researchers have shortened to “EVOLVE,” will adapt treatment plans in near real-time by analyzing changes in a patient’s cancer and matching it to the most promising therapy. “This has the potential to be practice-changing,” said Bill Schaller, the Lineberger Center’s director of communications. “This trial could pave the way for a new, more dynamic approach to treatment.” “Despite progress in treating breast cancer during the past 30 years, we still lack curative therapies for metastatic disease,” said Dr. Lisa Carey, the deputy director of clinical sciences at the Lineberger Center and the study’s le...